Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 8/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513273 | 0.81 | ALDH1A1 (0.40) | ITGA4ITGB7RAB9AALDH1A1ITGB1 | |
| SCHEMBL28615978 | 0.78 | ALDH1A1 (0.38) | ITGA4ITGB7RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL8280366 | 0.78 | ITGA4 (0.54) | ITGA4ITGB7RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL510385 | 0.78 | ACLY (0.35) | CRHR1ITGA4ITGB7ALDH1A1ITGB1 | |
| SCHEMBL919618 | 0.76 | L3MBTL1 (0.40) | ITGA4ITGB7RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL22016864 | 0.74 | ALDH1A1 (0.41) | ITGA4ITGB7RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL21835475 | 0.74 | MAPT (0.45) | ITGA4ITGB7RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29384915 | 0.74 | MAPT (0.45) | ITGA4ITGB7RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL919619 | 0.71 | ITGA4 (0.49) | ITGA4ITGB7ITGB1 | |
| SCHEMBL15344226 | 0.70 | KDM4E (0.38) | CRHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507410-B2 | Pyridazinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20120028988-A1 | USE OF PYRIDAZINONE COMPOUND FOR CONTROL OF HARMFUL ARTHROPOD PESTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | C5, C1S, WEE1 | CRHR1 667/4885ITGA4 2718/4885ITGB7 1974/4885 |
| US-20120028988-A1 | USE OF PYRIDAZINONE COMPOUND FOR CONTROL OF HARMFUL ARTHROPOD PESTS | PLPBP, PNPO, PIR | CRHR1 4613/4885ITGA4 1752/4885ITGB7 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.